I

Ionis Pharmaceuticals

D
IONS
USD
-0.35
(-0.9021%)
Market Closed
29,711.00
Volume
-4.598
EPS
-
Div Yield
-15.257937
P/E
6,063,991,448.95
Market Cap
Today
-1.5869%
1 Week
0.182%
1 Month
1.558%
6 Months
-6.174%
12 Months
-19.443%
Year To Date
-23.982%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
ALNY
ALNY
-0.795
(-0.2913%)
USD
B
BIIB
-0.32
(-0.1837%)
USD
REGN
REGN
8.505
(1.0417%)
USD
S
SRPT
-2.57
(-2.0903%)
USD
VRTX
VRTX
2.47
(0.494%)
USD
GILD
GILD
6.23
(6.7946%)
USD
A
ACAD
1.42
(8.993%)
USD
B
BMRN
0.785
(1.1869%)
USD
C
CRSP
1.15
(2.2656%)
USD

Title:
Ionis Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Do you need help or have a question?
Contact Us